| [1] |
马爱静, 赵雁林. 耐药结核病的流行和监测现状. 中国抗生素杂志, 2018, 43(5):502-506. doi: 10.3969/j.issn.1001-8689.2018.05.002.
doi: 10.3969/j.issn.1001-8689.2018.05.002
|
| [2] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
| [3] |
陈浩, 武楠楠, 胡文辉, 等. 抗结核药物作用新靶点及其研究进展. 中国防痨杂志, 2020, 42(3):286-292. doi: 10.3969/j.issn.1000-6621.2020.03.020.
doi: 10.3969/j.issn.1000-6621.2020.03.020
|
| [4] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8):723-732. doi: 10.1056/NEJMoa1313865.
doi: 10.1056/NEJMoa1313865
URL
|
| [5] |
Cox E, Laessig K. FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med, 2014, 371(8):689-691. doi: 10.1056/NEJMp1314385.
doi: 10.1056/NEJMp1314385
URL
|
| [6] |
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization, 2013.
|
| [7] |
World Health Organization. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis: a review of available evidence (2016), 28-29 June 2016, Geneva, Switzerland. Geneva: World Health Organization, 2017.
|
| [8] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814
URL
|
| [9] |
Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J, 2005, 25(3):564-569. doi: 10.1183/09031936.05.00111304.
doi: 10.1183/09031936.05.00111304
pmid: 15738303
|
| [10] |
World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018.
|
| [11] |
Gygli SM, Keller PM, Ballif M, et al. Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019, 63(4):e02175-18. doi: 10.1128/AAC.02175-18.
doi: 10.1128/AAC.02175-18
|
| [12] |
Liu Y, Gao M, Du J, et al. Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis, 2021, 73(9):e3391-e3397. doi: 10.1093/cid/ciaa1002.
doi: 10.1093/cid/ciaa1002
URL
|
| [13] |
李东硕, 王彬, 陆宇, 等. 结核分枝杆菌膜蛋白MmpS5-MmpL5的表达及功能研究. 中国防痨杂志, 2022, 44(3):227-233. doi: 10.19982/j.issn.1000-6621.20210587.
doi: 10.19982/j.issn.1000-6621.20210587
|
| [14] |
Xia H, Zheng Y, Liu D, et al. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. Microbiol Spectr, 2021, 9(3):e00409-21. doi: 10.1128/Spectrum.00409-21.
doi: 10.1128/Spectrum.00409-21
|
| [15] |
Du J, Gao J, Yu Y, et al. Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination. Front Microbiol, 2021, 12:655653. doi: 10.3389/fmicb.2021.655653.
doi: 10.3389/fmicb.2021.655653
URL
|
| [16] |
Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M.tuberculosis isolates. J Infect, 2020, 80(5):527-535. doi: 10.1016/j.jinf.2020.01.007.
doi: S0163-4453(20)30031-1
pmid: 31981638
|
| [17] |
张玉霞, 熊瑜, 常婷婷, 等. 含贝达喹啉方案治疗耐药肺结核的不良反应分析. 中国防痨杂志, 2022, 44(3):239-245. doi: 10.19982/j.issn.1000-6621.20210702.
doi: 10.19982/j.issn.1000-6621.20210702
|
| [18] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004
URL
|
| [19] |
Mohr E, Hughes J, Reuter A, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur Respir J, 2018, 51(6):1800017. doi: 10.1183/13993003.00017-2018.
doi: 10.1183/13993003.00017-2018
URL
|
| [20] |
Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med, 2019, 7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2.
doi: 10.1016/S2213-2600(19)30366-2
URL
|
| [21] |
谢莉, 朱慧, 高静韬, 等. 贝达喹啉血药浓度在耐药肺结核治疗中的变化及其与QTc间期延长的相关性. 中国防痨杂志, 2022, 44(3):219-226. doi: 10.19982/j.issn.1000-6621.20210696.
doi: 10.19982/j.issn.1000-6621.20210696
|
| [22] |
首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 抗结核药治疗药物监测临床应用专家共识. 中国防痨杂志, 2021, 43(9):867-873. doi: 10.3969/j.issn.1000-6621.2021.09.003.
doi: 10.3969/j.issn.1000-6621.2021.09.003
|
| [23] |
吴桂辉, 马瑶, 蔡阳, 等. 含贝达喹啉方案治疗艾滋病合并原发广泛耐药肺结核患者一例. 中国防痨杂志, 2022, 44(3):299-302. doi: 10.19982/j.issn.1000-6621.20210705.
doi: 10.19982/j.issn.1000-6621.20210705
|
| [24] |
Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother, 2016, 71(4):1037-1040. doi: 10.1093/jac/dkv447.
doi: 10.1093/jac/dkv447
URL
|
| [25] |
World Health Organization. Rapid communication: key changes to treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2019.
|
| [26] |
Achar J, Hewison C, Cavalheiro AP, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis, 2017, 23(10):1711-1713. doi: 10.3201/eid2310.170303.
doi: 10.3201/eid2310.170303
URL
|
| [27] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814
URL
|
| [28] |
吴妍, 李琦. 老年肺结核的诊治现状与进展. 中国防痨杂志, 2015, 37(9):975-978. doi: 10.3969/j.issn.1000-6621.2015.09.012.
doi: 10.3969/j.issn.1000-6621.2015.09.012
|
| [29] |
World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17-19 November 2020. Geneva: World Health Organization, 2021.
|
| [30] |
陈磊, 郭海萍, 逄宇, 等. GSK656和阿米卡星对脓肿分枝杆菌的体外联合药敏研究. 中国防痨杂志, 2022, 44(3):234-238. doi: 10.19982/j.issn.1000-6621.20210465.
doi: 10.19982/j.issn.1000-6621.20210465
|
)
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
